GYBYS(SH:600332) Tianfeng Securities·2024-03-17 16:00Investment Rating - The report maintains a "Buy" rating for the company [5][4] Core Insights - The company achieved a revenue of 75.15 billion yuan in 2023, representing a year-on-year growth of 6.68%. The net profit attributable to the parent company was 4.06 billion yuan, with a year-on-year increase of 2.25% [2][4] - The company is focusing on enhancing its operational efficiency through cost reduction strategies and innovation in product offerings, particularly in the health sector [3][4] - The forecast for 2024-2025 shows a slight downward adjustment in revenue and net profit estimates, with projected revenues of 81.54 billion yuan and 88.22 billion yuan for 2024 and 2025, respectively [4][5] Financial Data Summary - Revenue (in million yuan): - 2022: 70,788.16 - 2023: 75,515.40 - 2024E: 81,536.82 - 2025E: 88,223.36 - 2026E: 95,709.95 - Net Profit (in million yuan): - 2022: 3,966.52 - 2023: 4,055.68 - 2024E: 4,548.60 - 2025E: 5,014.57 - 2026E: 5,545.24 - EPS (in yuan/share): - 2022: 2.44 - 2023: 2.49 - 2024E: 2.80 - 2025E: 3.08 - 2026E: 3.41 - P/E Ratio: - 2022: 12.38 - 2023: 12.11 - 2024E: 10.80 - 2025E: 9.79 - 2026E: 8.86 [1][4][8]